Back to top
more

HCA Healthcare (HCA)

(Delayed Data from NYSE)

$373.33 USD

373.33
1,136,838

+7.18 (1.96%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $373.22 -0.11 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (58 out of 246)

Industry: Medical - Hospital

Zacks News

Sapna Bagaria headshot

Hospital Industry's Dull Near-Term Outllook Induced by Coronavirus

Revenue loss and cost rise due to coronavirus outbreak put hospital companies in a tight spot.

Zacks.com headshot

MEDNAX Plunges More Than 42% YTD: Will the Stock Rebound?

Even though MEDNAX (MD) endures the COVID-19 impact on global economy, it holds prospects to revive its fortunes with the help of its initiatives and strong fundamentals.

Zacks.com headshot

Here's Why You Should Stay Away From HCA Healthcare Now

Depressed revenues and elevated expenses make HCA Healthcare (HCA) an unattractive bet.

Zacks Equity Research

Why Is HCA (HCA) Up 1.8% Since Last Earnings Report?

HCA (HCA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Ensign Group's (ENSG) Q1 Earnings Beat, Revenues Up Y/Y

Ensign Group's (ENSG) first-quarter 2020 results reflect strong revenues courtesy of robust segmental performance, partly offset by high costs.

Zacks Equity Research

MEDNAX Divests American Anesthesiology to Avoid Cash Losses

MEDNAX (MD) sells its American Anesthesiology to NAPA for portfolio rationalization and averting the negative COVID-19 impact.

Zacks Equity Research

MEDNAX's (MD) Earnings Miss Estimates in Q1, Tumble Y/Y

MEDNAX's (MD) Q1 results reflect the coronavirus adversities that drained its revenues and volumes.

    Zacks Equity Research

    Tenet Healthcare (THC) Q1 Earnings Beat Estimates, Rise Y/Y

    Tenet Healthcare's (THC) Q1 results reflect a strong operating performance and an income tax benefit, partly offset by the coronavirus outbreak.

    Zacks Equity Research

    Humana's (HUM) Earnings Beat Estimates in Q1, Improve Y/Y

    Humana's (HUM) first-quarter results reflect better revenues and growth in Medicare Advantage business.

    Zacks Equity Research

    Community Health (CYH) Q1 Earnings & Revenues Miss Estimates

    Community Health's (CYH) Q1 results hurt by softer revenues due to decline in admissions.

    Zacks Equity Research

    Anthem's (ANTM) Q1 Earnings Miss Estimates, Improve Y/Y

    Anthem's (ANTM) Q1 results reflect solid growth across Government Business, offset by weak performance of Commercial & Specialty Business and Other segments.

    Zacks Equity Research

    Universal Health (UHS) Q1 Earnings, Revenues Miss Estimates

    Universal Health's (UHS) first-quarter earnings reflect pre-tax unrealized loss and higher expenses.

    Zacks Equity Research

    Stock Market News for Apr 22, 2020

    U.S. equities ended sharply lower on Tuesday, dragging the three major benchmarks to their lowest levels in about two weeks.

    Zacks Equity Research

    HCA Holdings (HCA) Q1 Earnings and Revenues Miss Estimates

    HCA (HCA) delivered earnings and revenue surprises of -10.73% and -1.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Equity Research

    HCA Healthcare's (HCA) Earnings Miss in Q1, Decrease Y/Y

    HCA Healthcare's (HCA) Q1 earnings take a hit from the coronavirus outbreak inducing lower patient volumes.

      Zacks Equity Research

      HCA Healthcare (HCA) to Report Q1 Earnings: What's in Store?

      HCA Healthcare's (HCA) Q1 results are likely to reflect weak volumes from the coronavirus effect.

      Zacks Equity Research

      Earnings Preview: HCA Holdings (HCA) Q1 Earnings Expected to Decline

      HCA (HCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Zacks Equity Research

      MEDNAX Plunges More Than 54% YTD: Will the Stock Rebound?

      Even though MEDNAX (MD) endures the COVID-19 impact on global economy, it holds high prospects to revive its fortunes by virtue of its solid fundamentals.

      Zacks Equity Research

      MEDNAX Provides Updates Related to Coronavirus Pandemic

      MEDNAX (MD) takes several steps to help fight the COVID-19 pandemic.

      Zacks Equity Research

      Community Health Repeals 2020 Outlook Amid Coronavirus Woes

      Community Health (CYH) withdraws its current-year guidance amid prevalent market volatility induced by the COVID-19 spread.

      Zacks Equity Research

      HCA Healthcare, Google Cloud Tie Up Amid Coronavirus Woes

      HCA Healthcare (HCA) partners Google Cloud and SADA for the COVID-19 National Response Portal, a platform to provide real-time COVID-19 updates.

      Zacks Equity Research

      Select Medical Revokes Full-Year View Amid Coronavirus Blues

      Plagued by business uncertainty from the coronavirus outbreak, Select Medical (SEM) ditches its 2020 earnings guidance.

      Zacks Equity Research

      Tenet Healthcare (THC) Gets Rating Actions From Moody's

      Tenet Healthcare (THC) gets specific rating actions from credit rating agency Moody's. The outlook of the ratings is stable.

      Zacks Equity Research

      HCA Healthcare Makes Cost-Control Efforts Amid Coronavirus Woes

      HCA Healthcare (HCA) trims headcount to contain costs as its revenues are under pressure.

      Zacks Equity Research

      Tenet Heathcare Scraps Q1 & 2020 Guidance Amid Coronavirus Chaos

      Tenet Heathcare (THC) nullifies its first-quarter and 2020 outlook due to the COVID-19 pandemic.